SKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit

Core Points - Skye Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing molecules targeting G protein-coupled receptors to treat obesity and metabolic diseases, with nimacimab as its lead product candidate [1] - A class action lawsuit has been filed on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025, alleging that the company misled investors about the viability of nimacimab [1][2] - The lawsuit claims that during the class period, Skye failed to disclose that nimacimab was less effective than represented, leading to overstated clinical and commercial prospects [2] Company Developments - On October 6, 2025, Skye released topline data from its 26-week Phase 2a CBeyond™ study of nimacimab, revealing that the drug did not achieve the primary endpoint of weight loss compared to placebo, and indicated lower than expected drug exposure [3] - Following the announcement, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share on the same day [3] Legal Actions - Shareholders interested in participating in the class action must submit their papers by January 16, 2026, to serve as lead plaintiff, representing other class members in the litigation [4] - Shareholders are not required to participate in the case to be eligible for recovery, and can choose to remain absent class members [4]